Incyte's Opzelura slapped with vitiligo delay amid topical JAK's eczema launch

As Incyte Corporation’s recently-minted Opzelura gets off to the races in eczema, the drug has run up against a setback in another dermatology indication.

The FDA has delayed its decision on Incyte’s drug in vitiligo by three months. The regulator now plans to deliver a verdict on the topical JAK inhibitor, also known as ruxolitinib cream, by July 18, Incyte said in a release.